BIND Therapeutics Inc (BIND)

0.14
0.01 3.33
OTC : Health Care
Prev Close 0.15
Open 0.15
Day Low/High 0.14 / 0.16
52 Wk Low/High 0.00 / 0.00
Volume 562.16K
Avg Volume 1.20M
Exchange OTC
Shares Outstanding 20.89M
Market Cap 16.29M
EPS -1.80
P/E Ratio N/A
Div & Yield N.A. (N.A)
BIND Therapeutics Reports Second Quarter 2015 Financial Results And Provides Corporate Update

BIND Therapeutics Reports Second Quarter 2015 Financial Results And Provides Corporate Update

BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine company developing targeted and programmable therapeutics called Accurins TM, today reported financial results and business highlights for the second...

BIND Therapeutics To Report Second Quarter 2015 Financial Results On August 6, 2015

BIND Therapeutics To Report Second Quarter 2015 Financial Results On August 6, 2015

BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine company developing targeted and programmable therapeutics called Accurins TM, today announced it will host a conference call and live audio webcast on...

BIND Therapeutics Announces FDA Authorization Of First-in-Human Clinical Trial With AstraZeneca's Aurora B Kinase Inhibitor Accurin AZD2811

BIND Therapeutics Announces FDA Authorization Of First-in-Human Clinical Trial With AstraZeneca's Aurora B Kinase Inhibitor Accurin AZD2811

BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine company developing targeted and programmable therapeutics called Accurins™, today announced that the U.

Andrew Hirsch, President And CEO, BIND Therapeutics (Photo: Business Wire)

Andrew Hirsch, President And CEO, BIND Therapeutics (Photo: Business Wire)

BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine company developing targeted and programmable therapeutics called Accurins™, today announced that Andrew Hirsch has been appointed president and...

BIND Therapeutics To Present At JMP Securities Life Sciences Conference 2015

BIND Therapeutics To Present At JMP Securities Life Sciences Conference 2015

BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine company developing targeted and programmable therapeutics called Accurins TM, announced today that Andrew Hirsch, BIND's president and chief executive...

BIND Therapeutics And Macrophage Therapeutics Announce Collaboration To Engineer CD206 Targeted Accurin™ Nanoparticle Using Manocept™ Macrophage Targeting Platform

BIND Therapeutics And Macrophage Therapeutics Announce Collaboration To Engineer CD206 Targeted Accurin™ Nanoparticle Using Manocept™ Macrophage Targeting Platform

BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine company developing targeted and programmable therapeutics called Accurins™, and Macrophage Therapeutics, a subsidiary of Navidea...

BIND Therapeutics Reports First Quarter 2015 Financial Results And Provides Corporate Update

BIND Therapeutics Reports First Quarter 2015 Financial Results And Provides Corporate Update

BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine company developing targeted and programmable therapeutics called Accurins TM, today reported financial results and business highlights for the quarter...

BIND Therapeutics To Report First Quarter 2015 Financial Results On May 7, 2015

BIND Therapeutics To Report First Quarter 2015 Financial Results On May 7, 2015

BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins™, today announced it will host a conference call and live audio...

BIND Therapeutics Presents Data Highlighting Ability Of Accurins To Control Biodistribution And Accumulate In Target Tissue At AACR Annual Meeting 2015

BIND Therapeutics Presents Data Highlighting Ability Of Accurins To Control Biodistribution And Accumulate In Target Tissue At AACR Annual Meeting 2015

BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins™, today announced that clinical and preclinical data from...

Bind Therapeutics (BIND) Strong On High Relative Volume Today

Bind Therapeutics (BIND) Strong On High Relative Volume Today

Trade-Ideas LLC identified Bind Therapeutics (BIND) as a strong on high relative volume candidate

Bind Therapeutics (BIND) Weak On High Volume

Bind Therapeutics (BIND) Weak On High Volume

Trade-Ideas LLC identified Bind Therapeutics (BIND) as a weak on high relative volume candidate

BIND Therapeutics Announces Extension Of Global Collaboration With Pfizer Inc. To Develop And Commercialize Multiple Accurins

BIND Therapeutics Announces Extension Of Global Collaboration With Pfizer Inc. To Develop And Commercialize Multiple Accurins

BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins™, today announced an extension of the terms of its global...

Data From Three Abstracts Validating Potential Of BIND Therapeutics' Accurins™ To Be Presented At American Association For Cancer Research Annual Meeting

Data From Three Abstracts Validating Potential Of BIND Therapeutics' Accurins™ To Be Presented At American Association For Cancer Research Annual Meeting

BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins, today announced the online availability of three abstracts that will...

BIND Therapeutics Reports Fourth Quarter And Full Year 2014 Financial Results

BIND Therapeutics Reports Fourth Quarter And Full Year 2014 Financial Results

BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins TM, today reported financial results for the fourth quarter and...

Andrew Hirsch (Photo: Business Wire)

Andrew Hirsch (Photo: Business Wire)

BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins™, today announced that Andrew Hirsch has been appointed the...

BIND Therapeutics To Report Fourth Quarter And Year-End 2014 Financial Results On March 11, 2015

BIND Therapeutics To Report Fourth Quarter And Year-End 2014 Financial Results On March 11, 2015

BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins TM, today announced it will host a conference call and live audio...

5 Stocks Under $10 Set to Soar: Sportsman's Warehouse and More

5 Stocks Under $10 Set to Soar: Sportsman's Warehouse and More

These under-$10 look ready to break out and trade higher from current levels.

BIND Therapeutics To Present At Cowen & Co. 35th Annual Healthcare Conference

BIND Therapeutics To Present At Cowen & Co. 35th Annual Healthcare Conference

BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins TM, announced today that Andrew Hirsch, BIND's chief operating officer...

BIND Therapeutics Announces Closing Of Public Offering Of Common Stock And Warrants To Purchase Common Stock

BIND Therapeutics Announces Closing Of Public Offering Of Common Stock And Warrants To Purchase Common Stock

BIND Therapeutics, Inc. (NASDAQ:BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins™, today announced the closing of its previously announced public...

BIND Therapeutics Prices Public Offering Of Common Stock And Warrants To Purchase Common Stock

BIND Therapeutics Prices Public Offering Of Common Stock And Warrants To Purchase Common Stock

BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins™, today announced the pricing of its underwritten public...

BIND Therapeutics Announces Proposed Public Offering Of Common Stock And Warrants To Purchase Common Stock

BIND Therapeutics Announces Proposed Public Offering Of Common Stock And Warrants To Purchase Common Stock

BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins™, today announced that it is commencing an underwritten public...

BIND Therapeutics Amends Credit Facility From Hercules Technology III, L.P. To Accelerate Accurin Pipeline Growth

BIND Therapeutics Amends Credit Facility From Hercules Technology III, L.P. To Accelerate Accurin Pipeline Growth

BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins TM, announced today that it has entered into an amendment of its...

BIND Therapeutics Co-Founder Publishes Nanotechnology Article In The Journal Of The American Medical Association

BIND Therapeutics Co-Founder Publishes Nanotechnology Article In The Journal Of The American Medical Association

BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins™, today announced the publication of an article in the Journal...

Bind Therapeutics (BIND) Highlighted As Weak On High Volume

Bind Therapeutics (BIND) Highlighted As Weak On High Volume

Trade-Ideas LLC identified Bind Therapeutics (BIND) as a weak on high relative volume candidate

Market News: Apple, Tesco, BIND Therapeutics

Market News: Apple, Tesco, BIND Therapeutics

The stock markets in the United States gained for the second day driven by speculations that central banks will continue to support economic growth. Sign up for our free daily newsletter Commenting on...

BIND Therapeutics Provides Clinical Update For BIND-014 And 2015 Strategic Overview

BIND Therapeutics Provides Clinical Update For BIND-014 And 2015 Strategic Overview

BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins™, today announced its 2015 strategic overview and enrollment of...

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: A, BH, EXPE, HMPR, NGVC, PCTI, PKOH, QADB, RSTI, SHBI Downgrades: MSON Initiations: BIND Read on to get TheStreet Quant Ratings' detailed report:

Bind Therapeutics Enters Oversold Territory (BIND)

Bind Therapeutics Enters Oversold Territory (BIND)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

BIND Therapeutics To Present At Oppenheimer 25th Annual Healthcare Conference

BIND Therapeutics To Present At Oppenheimer 25th Annual Healthcare Conference

BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins TM, announced today that Scott Minick, BIND's President and CEO,...

BIND Therapeutics Presents Positive Phase 2 Results Highlighting Potential Of BIND-014 As Novel Anti-Cancer Treatment At Q3W Dosing Schedule For Patients With Non-small Cell Lung Cancer At 26th EORTC-NCI-AACR Annual Symposium

BIND Therapeutics Presents Positive Phase 2 Results Highlighting Potential Of BIND-014 As Novel Anti-Cancer Treatment At Q3W Dosing Schedule For Patients With Non-small Cell Lung Cancer At 26th EORTC-NCI-AACR Annual Symposium

BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins TM, today presented positive results from its ongoing Phase 2...